natgillin/translations-raw huggingface dataset:
The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma randomised to receive single agent cisplatin.
U tablici koja slijedi navedene su učestalost i težina nuspojava koje su prijavljene u &gt; 5% od 168 bolesnika s mezoteliomom randomiziranih u skupinu koja je primala cisplatin i pemetreksed i 163 bolesnika s mezoteliomom randomiziranih u skupinu koja je primala samo cisplatin.
The table below provides the frequency and severity of undesirable effects that have been reported in &gt; 5 % of 265 patients randomly assigned to receive single agent pemetrexed with folic acid and vitamin B12 supplementation and 276 patients randomly assigned to receive single agent docetaxel.
U tablici koja slijedi navedena je učestalost i težina nuspojava koje su prijavljene u &gt; 5% od 265 bolesnika randomiziranih u skupinu koja je primala samo pemetreksed te nadomjestak folatne kiseline i vitamina B12 i 276 bolesnika randomiziranih u skupinu koja je primala samo docetaksel.
The table presents adverse reactions that occurred with an incidence &gt; 5% if the frequency was higher among Lyxumia treated patients than patients treated with all comparators.
Tablica prikazuje nuspojave koje su se javljale s incidencijom &gt; 5% ako je njihova učestalost bila viša među bolesnicima liječenima lijekom Lyxumia nego među onima koji su primali usporedne lijekove.
The table presents adverse reactions that occurred with an incidence &gt; 5% if the frequency was higher among Lyxumia treated patients than patients treated with all comparators.
Tablica prikazuje nuspojave koje su se javljale s incidencijom &gt; 5%, ako je njihova učestalost bila viša među bolesnicima liječenim lijekom Lyxumia nego među onima koji su primali usporedne lijekove.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12-14 g/dl.
Ciljna koncentracija hemoglobina u 2 studije bila je &gt; 13 g/dl; u ostale 3 studije bila je 12-14 g/dl.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12-14 g/dl.
Ciljna koncentracija hemoglobina u dva ispitivanja bila je &gt; 13 g/dl; u ostala tri ispitivanja bila je 12 – 14 g/dl.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12-14 g/dl.
Ciljna koncentracija hemoglobina u dva je ispitivanja bila &gt; 13 g/dl, a u preostala tri ispitivanja bila je 12 - 14 g/dl.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12-14 g/dl.
U dva ispitivanja ciljna koncentracija hemoglobina bila je &gt; 13 g/dl, a u preostala tri ispitivanja 12-14 g/dl.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12-14 g/dl.
U dva ispitivanja ciljna koncentracija hemoglobina bila je &gt; 13 g/dl, a u preostala tri ispitivanja od 12 do 14 g/dl.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12- 14 g/dl.
Ciljna koncentracija hemoglobina u dva je ispitivanja bila &gt; 13 g/dl, a u preostala tri ispitivanja bila je 12 - 14 g/dl.
The target haemoglobin concentration in two studies was &gt; 13 g/dl; in the remaining three studies it was 12- 14 g/dl.
Ciljna koncentracija hemoglobina u dva je ispitivanja bila &gt; 13 g/dl, a u preostala tri ispitivanja bila je između 12-14 g/dl.
The TECOS was a randomized study in 14,671 patients in the intention-to-treat population with an HbA1c of ≥ 6.5 to 8.0 % with established CV disease who received sitagliptin (7,332) 100 mg daily (or 50 mg daily if the baseline eGFR was ≥ 30 and &lt; 50 mL/min/1.73 m2) or placebo (7,339) added to usual care targeting regional standards for HbA1c and CV risk factors.
Ispitivanje TECOS bilo je randomizirano ispitivanje provedeno u 14 671 bolesnika, koji pripadaju populaciji bolesnika predviđenoj za liječenje, s vrijednostima HbA1c od ≥ 6,5 do 8,0% i potvrđenom KV bolesti te su primali sitagliptin (7332) u dozi od 100 mg na dan (ili 50 mg na dan ako je početni eGFR bio ≥ 30 i &lt; 50 ml/min/1,73 m2) ili placebo (7339) kao dodatak standardnom liječenju usmjerenom na regionalne standardne vrijednosti HbA1c i faktore KV rizika.
The TECOS was a randomized study in 14,671 patients in the intention-to-treat population with an HbA1c of ≥ 6.5 to 8.0 % with established CV disease who received sitagliptin (7,332) 100 mg daily (or 50 mg daily if the baseline eGFR was ≥ 30 and &lt; 50 mL/min/1.73 m2) or placebo (7,339) added to usual care targeting regional standards for HbA1c and CV risk factors.
Ispitivanje TECOS bilo je randomizirano ispitivanje provedeno u 14 671 bolesnika, koji pripadaju populaciji za koju je namijenjeno liječenje, s vrijednostima HbA1c od ≥ 6,5 do 8,0% i potvrđenom KV bolesti te su primali sitagliptin (7332) u dozi od 100 mg na dan (ili 50 mg na dan ako je početni eGFR bio ≥ 30 i &lt; 50 ml/min/1,73 m2) ili placebo (7339) kao dodatak standardnom liječenju usmjerenom na regionalne standardne vrijednosti HbA1c i faktore KV rizika.
The temperature should then be increased to &gt; 39°C (but not exceeding 40°C) in two different sites of measurement in the tumour area.
Temperatura se zatim povećava na &gt; 39°C (ali ne preko 40°C) na dva različita mjesta mjerenja u području tumora.
The terminal phase has not been covered unambiguously due to lack of data beyond 24 hours in paediatric subjects &lt; 6 years of age.
Završna faza nije jednoznačno obuhvaćena zbog nedostataka podataka nakon 24 sata u pedijatrijskih bolesnika &lt; 6 godina starosti.
The third major metabolite, M2, is &gt; 97% bound to plasma proteins.
Treći glavni metabolit, M2, vezan je za proteine plazme &gt; 97%.
The toxic range may be characterised by the following results of blood tests: Neutrophils &lt; 2,000/mm3
Raspon toksičnosti mogu određivati sljedeći nalazi krvnih pretraga: Neutrofili &lt; 2000/mm3
The treatment benefits of enoxaparin, evident for a number of efficacy outcomes, emerged at 48 hours, at which time there was a 35% reduction in the relative risk of myocardial re-infarction, as compared with unfractionated heparin (p &lt; 0.0001).
Koristi od liječenja enoksaparinom, dokazane čitavim nizom povoljnih ishoda, primijećene su za 48 sati, u kojih je relativni rizik reinfarkta miokarda smanjen za 35 %, u usporedbi sa skupinom liječenom nefrakcioniranim heparinom (p &lt; 0,0001).
The treatment benefits of enoxaparin, evident for a number of efficacy outcomes, emerged at 48 hours, at which time there was a 35% reduction in the relative risk of myocardial re-infarction, as compared with unfractionated heparin (p &lt; 0.0001).
Koristi od liječenja enoksaparinom, dokazane čitavim nizom povoljnih ishoda, primijećene su za 48 sati, u kojih je relativni rizik reinfarkta miokarda smanjen za 35%, u usporedbi sa skupinom liječenom nefrakcioniranim heparinom (p &lt; 0,0001).
The treatment benefits of enoxaparin, evident for a number of efficacy outcomes, emerged at 48 hours, at which time there was a 35% reduction in the relative risk of myocardial re-infarction, as compared with unfractionated heparin (p &lt; 0.0001).
Koristi od liječenja enoksaparinom, dokazane čitavim nizom povoljnih ishoda, primijećene su za 48 sati, u u kojih je relativni rizik reinfarkta miokarda smanjen za 35%, u usporedbi sa skupinom liječenom nefrakcioniranim heparinom (p &lt; 0,0001).
The trial was stopped early for efficacy reasons as a significantly longer time to relapse (p &lt; 0.0001, Figure 1) was seen in patients treated with Xeplion compared to placebo (hazard ratio = 4.32; 95% CI: 2.4-7.7).
Ispitivanje je zbog djelotvornosti prekinuto prije završetka, jer je u bolesnika koji su primali Xeplion zabilježeno značajno dulje vrijeme do ponovnog nastupa bolesti (p &lt; 0,0001; slika 1) u usporedbi s placebom (omjer rizika = 4,32; 95% CI: 2,4-7,7).
The two-year survival rates were 50.8 % in patients receiving azacitidine versus 26.2 % in patients receiving CCR (p &lt; 0.0001).
Stopa dvogodišnjeg preživljenja kod bolesnika liječenih azacitidinom je bila 50,8 % naspram 26,2 % kod bolesnika liječenih CCR-om (p &lt; 0,0001).
The type and incidence of adverse reactions in patients &gt; 55 years of age were similar to the ones in younger patients (see sections 4.2 and 5.2).
Vrsta i incidencija nuspojava u bolesnika &gt; 55 godina starosti bili su slični onima u mlađih bolesnika (vidjeti dijelove 4.2 i 5.2).
The unbound fraction of dolutegravir in plasma is increased at low levels of serum albumin ( &lt; 35 g/L) as seen in subjects with moderate hepatic impairment.
Udio nevezanog dolutegravira u plazmi povećava se pri niskim razinama albumina u serumu ( &lt; 35 g/l), što je primijećeno u ispitanika s umjerenim oštećenjem jetrene funkcije.
The urinary excretion of non-liposomal irinotecan is 11% to 20%; SN-38 &lt; 1%; and
Izlučivanje neliposomalnog irinotekana putem urina iznosi 11% do 20%; SN-38 &lt; 1%; a
The urinary excretion of unchanged bedaquiline was &lt; 0.001% of the dose in clinical studies, indicating that renal clearance of unchanged active substance is insignificant.
Eliminacija nepromijenjenog bedakilina putem mokraće bila je &lt; 0,001% doze u kliničkim ispitivanjima, što upućuje na to da bubrežni klirens nepromijenjene djelatne tvari nije značajan.
The use in patients with acute renal failure or creatinine clearance (CrCl) &lt; 30 ml/min including patients undergoing haemodialysis is contraindicated (see section 4.3).
Primjena je kontraindicirana kod bolesnika s akutnim zatajenjem bubrega ili kod onih kod kojih je klirens kreatinina (CrCl) &lt; 30 ml/min uključujući i bolesnike na hemodijalizi (vidjeti dio 4.3).
The use in patients with severe renal impairment (CLCR &lt; 30 ml/min) is not recommended (see sections 4.4 and 5.2).
Ne preporučuje se primjena u bolesnika s teškim oštećenjem funkcije bubrega (CLcr &lt; 30 ml/min) (vidjeti dijelove 4.4 i 5.2).
The use of Aclasta in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Primjena Aclaste u bolesnika s teškim oštećenjem bubrega (klirens kreatinina &lt; 35 ml/min) kontraindicirana je zbog povećanog rizika od zatajenja bubrega u toj populaciji.
The use of Dacogen as initial therapy was also evaluated in an open-label, single-arm, Phase II study (DACO-017) in 55 subjects &gt; 60 years with AML according to the WHO classification.
Primjena Dacogena kao početne terapije bila je također ispitivana u otvorenom ispitivanju faze II (DACO-017) provedenom na jednoj skupini od 55 ispitanika &gt; 60 godina s akutnom mijeloičnom leukemijom prema SZO klasifikaciji.
The use of Emtricitabine/Tenofovir disoproxil Zentiva is not recommended in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) and in patients who require haemodialysis since appropriate dose reductions cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Emtricitabine/Tenofovir disoproxil Zentiva ne preporučuje se za bolesnike s teškim oštećenjem bubrežne funkcije (klirens kreatinina &lt; 30 ml/min) i bolesnike kojima je potrebna hemodijaliza jer se kombiniranom tabletom ne mogu postići odgovarajuća smanjenja doze (vidjeti dijelove 4.2 i 5.2).
The use of ONIVYDE should be avoided in patients with bilirubin &gt; 2.0 mg/dl, or aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &gt; 2.5 times upper limit of normal (ULN) or &gt; 5 times ULN if liver metastasis is present (see section 4.4).
Primjenu lijeka ONIVYDE treba izbjegavati u bolesnika s razinom bilirubina &gt; 2,0 mg/dl ili vrijednostima aspartat aminotransferaze (AST) i alanin aminotransferaze (ALT) &gt; 2,5 puta iznad gornje granice normale (GGN) ili &gt; 5 puta GGN ako su prisutne metastaze u jetri (vidjeti dio 4.4).
The use of pirfenidone is contraindicated in patients with severe renal impairment (CrCl &lt; 30ml/min) or end stage renal disease requiring dialysis (see sections 4.2 and 4.3).
Primjena pirfenidona kontraindicirana je u bolesnika s teškim oštećenjem funkcije bubrega (CrCl &lt; 30ml/min) ili bolesnika u terminalnoj fazi bubrežne bolesti koja zahtijeva dijalizu (vidjeti dijelove 4.2 i 4.3).
The use of silodosin in patients with severe renal impairment (CLCR &lt; 30 ml/min) is not recommended (see sections 4.2 and 5.2).
Ne preporučuje se primjena silodozina u bolesnika s teškim oštećenjem funkcije bubrega (CLcr &lt; 30 ml/min) (vidjeti dijelove 4.2 i 5.2).
The use of sugammadex in patients with severe renal impairment (including patients requiring dialysis (CrCl &lt; 30 mL/min)) is not recommended (see section 4.4).
Ne preporučuje se primjena sugamadeksa u bolesnika s teškim oštećenjem funkcije bubrega (uključujući bolesnike na dijalizi (klirens kreatinina &lt; 30 ml/min)) (vidjeti dio 4.4).
The use of telmisartan in combination with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see section 4.3).
Istodobna primjena telmisartana s aliskirenom je kontraindicirana kod bolesnika s dijabetes melitusom ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dio 4.3).
The use of telmisartan in combination with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see section 4.3).
Primjena telmisartana u kombinaciji s aliskirenom je kontraindicirana kod bolesnika s dijabetes melitusom ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dio 4.3).
The use of Truvada is not recommended in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min) and in patients who require haemodialysis since appropriate dose reductions cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Primjena Truvade se ne preporučuje pacijentima s teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 30 mL/min) i pacijentima kojima je potrebna hemodijaliza, jer se kombiniranom tabletom ne može postići odgovarajuće smanjenje doze (vidjeti dio 4.2 i 5.2).
The use of warm ( &gt; 40°C) or carbonated beverages should be avoided.
Mora se izbjegavati primjena vrućih ( &gt; 40°C) ili gaziranih pića.
The use of Zoledronic Acid Hospira in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Primjena Zoledronatne kiseline Hospira u bolesnika s teškim oštećenjem bubrega (klirens kreatinina &lt; 35 ml/min) je kontraindicirana zbog povećanog rizika od zatajenja bubrega u ovoj populaciji.
The use of zoledronic acid in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population
Primjena zoledronatne kiseline u bolesnika s teškim oštećenjem bubrega (klirens kreatinina &lt; 35 ml/min), kontraindicirana je zbog povećanog rizika od zatajenja bubrega u toj populaciji.
The use of zoledronic acid in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Primjena zoledronatne kiseline u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 35 ml/min) kontraindicirana je zbog povećanog rizika od zatajenja bubrega u toj populaciji.
The use of Zoledronic acid Teva Generics in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Primjena Zoledronatne kiseline Teva Generics u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 35ml/min) kontraindicirana je zbog povećanog rizika od zatajenja bubrega u toj populaciji.
The use of Zoledronic acid Teva Pharma in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Primjena Zoledronatne kiseline Teva Pharma u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 35 ml/min) kontraindicirana je zbog povećanog rizika od zatajenja bubrega u toj populaciji.
The use of Zoledronic acid Teva Pharma in patients with severe renal impairment (creatinine clearance &lt; 35 ml/min) is contraindicated due to an increased risk of renal failure in this population.
Primjena Zoledronatne kiseline Teva Pharma u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 35ml/min) kontraindicirana je zbog povećanog rizika od zatajenja bubrega u toj populaciji.
The usual dose is recommended, except for decreased renal function with estimated glomerular filtration rate &lt; 60 mL/min/1.73 m2 where Cholib is contraindicated (see section 4.3).
Preporučuje se uobičajena doza, osim kod smanjene funkcije bubrega s procijenjenom brzinom glomerularne filtracije &lt; 60 ml/min/1,73 m2 gdje je Cholib kontraindiciran (vidjeti dio 4.3).
The vaccine response was defined as the proportion of subjects with: rSBA titres  32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre &lt; 8) at least a 4-fold increase in rSBA titres from pre- to post-vaccination for initially seropositive subjects (i.e., pre-vaccination rSBA titre ≥ 8)
Odgovor na cjepivo je definiran kao udio ispitanika s: rSBA titrima ≥ 32 za inicijalno seronegativne ispitanike (tj. rSBA titar &lt; 8 prije cijepljenja) najmanje četverostrukim porastom rSBA titra od onog prije do onog nakon cijepljenja za inicijalno seropozitivne ispitanike (tj. rSBA titar ≥ 8 prije cijepljenja)
The VIO study included patients with occult with no classic subfoveal CNV with a visual acuity score of 73-34 letters (20/40-20/200), and patients with lesions &gt; 4 MPS disc areas were to have baseline visual acuity &lt; 65 letters ( &lt; 20/50).
U ispitivanju VIO sudjelovali su bolesnici s prikrivenim, ali bez klasičnog subfovealnog CNV-a, s rezultatom vidne oštrine između 73 i 34 slova (20/40-20/200), i bolesnici s lezijama u &gt; 4 područja diskova u MPS-u koji su u početku morali imati vidnu oštrinu oka &lt; 65 slova ( &lt; 20/50).
The VIP-AMD included patients with occult with no classic subfoveal CNV with a visual acuity score of &gt; 50 letters (20/100).
U ispitivanje VIP-AMD bili su uključeni bolesnici s prikrivenim, ali bez klasičnog subfovealnog CNV-a s vidnom oštrinom &gt; 50 znakova (20/100).
The volume of distribution (Vd) for AsIII is large ( &gt; 400 L) indicating significant distribution into the tissues with negligible protein binding.
Volumen distribucije (Vd) za AsIII je velik ( &gt; 400 l) što ukazuje na značajnu raspodjelu u tkiva sa zanemarivim vezivanjem na proteine.
The week 48 results from the pooled analysis of DUET-1 and DUET-2 demonstrated that the INTELENCE arm was superior to the placebo arm irrespective of whether ENF was used de novo (p = 0.0199) or not (p &lt; 0.0001).
Rezultati analize podataka iz 48. tjedna ispitivanja DUET-1 i DUET-2 pokazali su da je skupina koja je primala INTELENCE bila superiorna u odnosu na skupinu koja je primala placebo bez obzira na to je li ENF primjenjivan (p = 0,0199) ili nije primjenjivan (p &lt; 0,0001) de novo.
The younger patients with the severe phenotype ( &lt; 2.5 years) and all 4 patients with the intermediate phenotype exhibited a normal rate of mental development, whereas the older patients with a severe phenotype made limited or no gains in cognition.
Kod mlađih bolesnika s teškim fenotipom ( &lt; 2,5 godina) i kod sva 4 bolesnika s intermedijarnim fenotipom primijećen je normalan mentalni razvoj, dok je kod starijih bolesnika s teškim fenotipom zabilježeno malo ili nikakvo kognitivno poboljšanje.
The zoledronic acid group revealed approximately 2.5 mm less height loss compared to placebo (95% CI: 1.6 mm, 3.5 mm) [p &lt; 0.0001].
Skupina na zoledronatnoj kiselini pokazala je otprilike 2,5 mm manji gubitak tjelesne visine u usporedbi s placebom (95% CI: 1,6 mm, 3,5 mm) [p &lt; 0,0001].
The “primary” statistical test for “response” was the trend test of CR versus PR versus non-response (p &lt; 0.0001)
“Primarni” statistički test za “odgovor” bio je trend test: CR naspram PR naspram izostanak odgovora (p &lt; 0,0001)
The “primary” statistical test for “response” was the trend test of CR versus PR versus non-response (p &lt; 0.0001)
“Primarni” statistički test za “odgovor” bio je trend test: CR u odnosu na PR u odnosu na izostanak odgovora (p &lt; 0,0001)
Their frequency is defined using the following conventions: common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Njihova je učestalost definirana na sljedeći način: česte (≥1/100 do &lt; 1/10); manje česte (≥1/1000 do &lt; 1/100); rijetke (≥1/10 000 do &lt; 1/1000); vrlo rijetke ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Their frequency is defined using the following conventions: common (≥1/100 to
Njihova je učestalost definirana na sljedeći način: česte (≥1/100, &lt; 1/10); manje česte (≥1/1000,
Their frequency is defined using the following conventions: common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000) , not known (cannot be estimated from the available data).
&lt; 1/100); rijetke (≥1/10 000, &lt; 1/1000); vrlo rijetke ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Their frequency is defined using the following conventions: common (1/100 to &lt; 1/10); uncommon (1/1,000 to &lt; 1/100); rare (1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
&lt; 1/100); rijetke (≥1/10 000, &lt; 1/1000); vrlo rijetke ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Their frequency is defined using the following conventions: common (1/100 to &lt; 1/10); uncommon (1/1,000 to &lt; 1/100); rare (1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Njihova je učestalost definirana na sljedeći način: česte (≥ 1/100, &lt; 1/10); manje česte (≥ 1/1000, &lt; 1/100); rijetke (≥ 1/10 000, &lt; 1/1000); vrlo rijetke ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Their frequency is defined using the following conventions: common (1/100 to &lt; 1/10); uncommon (1/1,000 to &lt; 1/100); rare (1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Njihova je učestalost definirana na sljedeći način: česte (≥1/100 i &lt; 1/10); manje česte (≥1/1000 i &lt; 1/100); rijetke (≥1/10 000 i &lt; 1/1000); vrlo rijetke ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Themedian times to progression in these endpoints ranged from 0.7 to 2.1 months longer for TMZ than for procarbazine (log rank p = &lt; 0.01 to 0.03).
Medijan vremena do progresije bolesti prema ovim mjerama ishoda bio je za 0,7 do 2,1 mjeseca dulji u skupini koja je primala TMZ nego u skupini koja je primala prokarbazin (log-rang p = &lt; 0,01 do 0,03).
Then, if ANC remains &gt; 1.0 x 109 /l for 3 more consecutive days
Potom, ako ABN ostane &gt; 1,0 x 109/l tijekom najmanje 3 uzastopna dana
Then, if ANC remains &gt; 1.0 x 109/L for 3 more consecutive days
Potom, ako je ukupni broj neutrofila &gt; 1,0x109/l tijekom najmanje 3 uzastopna dana
Then, if ANC remains &gt; 1.0 x 109/L for 3 more consecutive days
Zatim, ako ABN ostane &gt; 1,0 x 109/l tijekom još 3 uzastopna dana
Then, if ANC remains &gt; 1.0 x 109/L for 3 more consecutive days
Zatim, ako ABN ostane &gt; 1,0x109/l tijekom još 3 uzastopna dana
Then, if ANC remains &gt; 1.0 x 109/l for 3 more consecutive days
Zatim, ako ANC ostane &gt; 1,0 x 109/l tijekom još 3 uzastopna dana